Furthermore, as DNA2 plays a role in DSB repair via HR pathways, the combination of d16 and PARPis can be utilized as a synthetic lethal therapy in BRCA1- and or BRCA2-proficient cancer cells and xenografts. The gene discussed is BRCA2; the disease is cancer.